Lv1
90 积分 2024-04-23 加入
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
20天前
已完结
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
20天前
已完结
Health Care Quality and Patient Safety in the Era of Artificial Intelligence
1个月前
已关闭
Eradicating measurable residual disease via immunotherapy to cure acute lymphoblastic leukemia: current status and future directions
4个月前
已完结
皖公网安备34019202002308
